cefadroxil Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, cefalosporanic acid derivatives	526	50370-12-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cefadroxil cefadrox cephadroxil cefadroxil hemihydrate	Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative. Molecular weight: 363.39 Formula: C16H17N3O5S CLOGP: -2.51 LIPINSKI: 0 HAC: 8 HDO: 4 TPSA: 132.96 ALOGS: -2.96 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cefadroxil
cefadrox
cephadroxil
cefadroxil hemihydrate

Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.

Molecular weight: 363.39
Formula: C16H17N3O5S
CLOGP: -2.51
LIPINSKI: 0
HAC: 8
HDO: 4
TPSA: 132.96
ALOGS: -2.96
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	14.20 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	93 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	78.62 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	95 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.23 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.50 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.39 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.10 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Feb. 17, 1978	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Type IV hypersensitivity reaction	262.18	23.70	48	1356	2492	46682166
Rash maculo-papular	127.80	23.70	43	1361	27831	46656827
Oedema	64.43	23.70	34	1370	67037	46617621
Drug hypersensitivity	53.98	23.70	50	1354	243775	46440883
Veillonella infection	28.44	23.70	4	1400	36	46684622
Drug reaction with eosinophilia and systemic symptoms	28.35	23.70	15	1389	29533	46655125
Neisseria infection	27.63	23.70	4	1400	45	46684613
Cellulitis	24.94	23.70	19	1385	70269	46614389
Stomatococcal infection	24.70	23.70	4	1400	98	46684560
Immunodeficiency common variable	24.09	23.70	4	1400	115	46684543

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event

Pharmacologic Action:

Source	Code	Description
ATC	J01DB05	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS First-generation cephalosporins
CHEBI has role	CHEBI:36047	antibacterial drugs
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Streptococcal tonsillitis	indication	41582007
Klebsiella cystitis	indication	60867007
Urinary tract infectious disease	indication	68566005
Tonsillitis	indication	90176007	DOID:10456
Escherichia coli urinary tract infection	indication	301011002
Proteus urinary tract infection	indication	301012009
Streptococcus pyogenes infection	indication	302809008
Infection due to Staphylococcus aureus	indication	406602003
Prevention of Bacterial Endocarditis	off-label use
Impaired renal function disorder	contraindication	197663003
Pseudomembranous enterocolitis	contraindication	397683000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.77	acidic
pKa2	9.72	acidic
pKa3	13.53	acidic
pKa4	7.63	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Solute carrier family 15 member 1	Transporter	P46059	S15A1_HUMAN		Ki	2.14		WOMBAT-PK
Bacterial penicillin-binding protein	Enzyme		DACA_ECOLI DACB_ECOLI DACC_ECOLI FTSI_ECOLI PBP2_ECOLI PBPA_ECOLI PBPB_ECOLI	INHIBITOR				CHEMBL	CHEMBL

External reference:

ID	Source
4018151	VUID
N0000146488	NUI
D00257	KEGG_DRUG
66592-87-8	SECONDARY_CAS_RN
4018151	VANDF
C0007538	UMLSCUI
CHEBI:53667	CHEBI
CHEMBL1644	ChEMBL_ID
DB01140	DRUGBANK_ID
D002434	MESH_DESCRIPTOR_UI
47965	PUBCHEM_CID
4831	IUPHAR_LIGAND_ID
280111G160	UNII
1297878	RXNORM
d00080	MMSL
004959	NDDF
13414000	SNOMEDCT_US
372651006	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3196	CAPSULE	500 mg	ORAL	ANDA	22 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	0093-4059	TABLET	1000 mg	ORAL	ANDA	23 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9766	POWDER, FOR SUSPENSION	500 mg	ORAL	ANDA	21 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9767	POWDER, FOR SUSPENSION	250 mg	ORAL	ANDA	21 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9947	CAPSULE	500 mg	ORAL	ANDA	21 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9948	TABLET, FILM COATED	1 g	ORAL	ANDA	23 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	10544-135	CAPSULE	500 mg	ORAL	ANDA	19 sections
CEFADROXIL	Human Prescription Drug Label	1	16590-043	CAPSULE	500 mg	ORAL	ANDA	23 sections
Cefadroxil	Human Prescription Drug Label	1	16714-388	CAPSULE	500 mg	ORAL	ANDA	21 sections
Cefadroxil	Human Prescription Drug Label	1	16714-389	POWDER, FOR SUSPENSION	250 mg	ORAL	ANDA	21 sections
Cefadroxil	Human Prescription Drug Label	1	16714-390	POWDER, FOR SUSPENSION	500 mg	ORAL	ANDA	21 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	21695-427	CAPSULE	500 mg	ORAL	ANDA	22 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	33261-018	CAPSULE	500 mg	ORAL	ANDA	19 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	42254-146	CAPSULE	500 mg	ORAL	ANDA	19 sections
CEFADROXIL	Human Prescription Drug Label	1	42549-504	CAPSULE	500 mg	ORAL	ANDA	23 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-553	CAPSULE	500 mg	ORAL	ANDA	19 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-595	CAPSULE	500 mg	ORAL	ANDA	21 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	45865-503	CAPSULE	500 mg	ORAL	ANDA	19 sections
Cefadroxil	Human Prescription Drug Label	1	50090-1915	CAPSULE	500 mg	ORAL	ANDA	21 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	52959-428	CAPSULE	500 mg	ORAL	ANDA	19 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	53002-2290	CAPSULE	500 mg	ORAL	ANDA	19 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	54868-3742	CAPSULE	500 mg	ORAL	ANDA	13 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5693	POWDER, FOR SUSPENSION	250 mg	ORAL	ANDA	14 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5694	POWDER, FOR SUSPENSION	500 mg	ORAL	ANDA	14 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	55289-589	CAPSULE	500 mg	ORAL	ANDA	21 sections
Cefadroxil	Human Prescription Drug Label	1	57237-096	CAPSULE	500 mg	ORAL	ANDA	21 sections
Cefadroxil	Human Prescription Drug Label	1	57237-097	POWDER, FOR SUSPENSION	250 mg	ORAL	ANDA	21 sections
Cefadroxil	Human Prescription Drug Label	1	57237-098	POWDER, FOR SUSPENSION	500 mg	ORAL	ANDA	21 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	57297-180	CAPSULE	500 mg	ORAL	ANDA	19 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	63187-883	CAPSULE	500 mg	ORAL	ANDA	19 sections